ArticleBone reports2026
The epidemiology of cancer patients with proximal femoral lesions and evaluation of surgical decision tools: A prospective cohort study.
Article in Bone reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This study evaluated the outcomes of orthopaedic oncological surgical decisions in cancer patients with proximal femoral lesions and the accuracy of fracture prediction tools. Methods: Patients with proximal femur metastatic cancer or multiple myeloma lesions presenting for prophylactic surgical evaluation between March 2018 and July 2023 were recruited with follow-up until March 2026. Femoral fracture risk was evaluated using CT finite element analysis (CTFEA) and Mirels' score. Patients were randomized, enabling 2/3 of their surgeons to receive the results of their CTFEA. Results: One hundred and ten patients completed the study. The patient 36-month patient survival rate from the time of orthopaedic oncology referral was 44%, with no difference in the survival estimates of patients who underwent prophylactic surgery and patients with no surgery ( Conclusion: Compared to publications prior to modern therapy, patient survival improved. Having prophylactic proximal femur surgery because of metastasis was not found to affect survival time. While CTFEA correctly identified all four fracture patients, following its prophylactic surgery recommendations would have led to unnecessary surgeries. Orthopaedic oncologists disregarded the CTFEA recommendation to perform surgery in 25% of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.